2020: IAG’s Imaging in Clinical Research Summary
We all at IAG, Image Analysis Group want to wish you happy holidays and successful closing of this unprecedented year! This year asked us all to call on our best selves and find new ways to support our teams and community, adapt and thrive, despite the circumstances.
At IAG, we spent this year finding efficient ways to share our expertise and keep up the work despite covid19.
‘We want to thank our partners, clients, and collaborators for placing your trust in our team! We are here to support you in the tough times and for year to come,’ said Dr. Olga Kubassova, CEO of IAG, Image Analysis Group.
As you are coming to a calmer period, there may be time to reflect on what could help your growth in 2021.
The list below details our 2020 webinars, papers, and partnerships. We hope these provide inspiration and guidance to your company’s growth and development plans!
Reach out to our team (email: email@example.com) with any questions or to set-up a follow-up call!
IAG’s imaging experts shared their experience in designing and delivering oncology clinical trials, that use quantitative imaging alongside the standard radiographic response criteria. Focus on central review vs local read with RECIST 1.1/iRECIST, RANO, Lugano, use of cloud for imaging data management and AI.
This webinar covered current challenges and introduced novel strategies and paradigms for decision making, including radiological phenotyping, quantification of pseudo progression and use of AI to answer efficacy questions and identify responders in trial of neuro-oncology.
This webinar delivered by Dr. Sven Kili, IAG’s Member of Scientific Advisory board and Cell & Gene Therapy Senior Leader focused on the optimisation of clinical development, regulatory pathways in the EU and USA, and value creation and investment proposition for cell and gene therapies.
IAG team and Dr. Lee Simon focused on the regulatory pathways for osteoarthritis drug development in the EU and USA and novel trial design vs FDA perspective.
Our expert team discussed the use of imaging in drug trials of Covid19 and broader, in lung diseases. The webinar covers imaging biomarkers for drugs in development, AI and modern infrastructure in relevance to Covid19 drug trials.
Together with Harvard medical school, Dr. Olga Kubassova spoke about the connection between the development of novel therapeutics and data sciences. She offered the practical use of imaging in clinical trials: patient stratification and drug efficacy.
IAG’s team detailed our experience in support i/o drug development, especially assessment of pseudo-progression through quantification of changes in the tumour microenvironment.
Following the success of the previous years, when IAG’s team joined forces with teams of Eli Lilly, IMV, Soricimed, Medicenna and others, we are excited to announce that this year, we partnered with several new biotech companies and academics.
IAG partnered with CNS Pharmaceuticals to support the development of novel treatments for primary and metastatic cancers of the central nervous system:
IAG partnered with ZiteLab to bring novel methodologies for assessment efficacy of drugs for Rheumatic Diseases into IAG’s DYNAMIKA platform:
IAG partnered with Novadip Biosciences to bring novel methods for CT and Xray analysis, which can objectively assess patient response to a novel cell-based therapy for Osseous Non-Union Indications:
IAG and Cellsight Technologies partner to maximize chances of success for Immuno-Oncology companies through the use of Advanced Imaging Strategies:
IAG Partnered with McMaster University to build advance multi-omics-based Machine Learning models for Glioblastoma drug development. The partners are building Machine Learning AI -driven models for tumour stratification and early assessment of drug efficacy.
Lastly, IAG & Takeda announced partnership in developing novel deep learning tools for assessment of histopathology slides from patients with Ulcerative Colitis:
This year, IAG’s scientific team presented over 20 abstracts at oncology and rheumatology conferences and presented new data in full papers and opinion pieces: https://www.ia-grp.com/publications/
Our goal is to accelerate novel drug development by using the right analytical tools and modern trial infrastructure. We take a broader view on the assets’ development and bring expertise in study design, execution, and commercialization. As needed, we deploy AI, Machine Learning, and smart image analysis methods to ensure the speed and cost-effectiveness of clinical programs. IAG’s team supports investors and biotech executive teams with deploying the right strategies for early efficacy assessments, objective response prediction and critical analysis of advanced treatment manifestations. Thus, lowering the investment risks into advanced therapies while helping to accelerate study outcomes. www.ia-grp.com
Engage with our team
Dr. Olga Kubassova, CEO: www.linkedin.com/in/olgakubassova/
David Chia, CCO: https://www.linkedin.com/in/jahyungdavidchia/
Dr. Diana Dupont-Roettger, Chief Scientific Alliance Officer: https://www.linkedin.com/in/dianaroettger/